at all scheduled visits, and antihypertensive treatment will be adjusted whenever ABP exceeds normal values (Figure). Results: MASTER will evaluate whether an ABPM based strategy is superior to an OBPM based strategy in changing LVmass and microalbuminuria (intermediate coprimary outcome) and in preventing CV events (secondary outcome). Conclusions: Although the superiority of ABPM over OBPM has been repeatedly shown by observational studies, key evidence from randomized intervention trials on the actual clinical value of ABPM is still missing. The results of the MASTER study will help to clarify whether an ABPM guided treatment strategy provides a greater benefit in terms of prevention/regression of organ damage and reduction in CV events than a strategy based on conventional OBP measurements. Background: Obesity is commonly associated with metabolic syndrome, which is well known to be a risk factor for diabetes and hypertension. However, whether obesity in the absence of metabolic syndrome ("healthy" obesity) confers similar or less risk is not known. We test the hypothesis that healthy obesity still carried increased risk for hypertension and diabetes. Methods: Study subjects consisted of Japanese adults between 30 and 85 years old were enrolled at a hospital and available at enrollment (2004) and at 5-year follow-up (2009). Subjects were excluded if they were hypertensive, diabetic, had a medication for dyslipidemia and/or gout or hyperuricemia in 2004. We divided
Background: Warfarin is widely used in clinical practice and excessive anticoagulation is a well-known complication of this therapy. Little is known about the risk factors for severe overanticoagulation. Purpose: We sought to investigate the occurrence and predicting factors for episodes with very high (≥9) international normalized ratio (INR) values in patients with atrial fibrillation (AF) on warfarin anticoagulation treatment. Methods: Excessive Warfarin Anticoagulation (EWA) study screened all patients (n=13618) in the University Hospital region with an INR ≥2 between 2003-2015. Patients using warfarin for AF with very high (≥9) INR values (EWA Group) were identified (n=412 patients) and their characteristics were compared to a control group (n=405) of AF patients with stable INR during long-term anticoagulation treatment.
Results:
The event of very high INR led to a bleeding event in over 25% (n=105) of patients. Of the several temporary and permanent EWA risk factors observed (Table) , strongest were excessive alcohol consumption in 9.6% of patients and reduced renal function. Recent antibiotic or antifungal medication, recent hospitalization or outpatient clinic visit and the first 6 months of warfarin use were the most significant temporary risk factors for EWA. Background: Obesity is commonly associated with metabolic syndrome, which is well known to be a risk factor for diabetes and hypertension. However, whether obesity in the absence of metabolic syndrome ("healthy" obesity) confers similar or less risk is not known. We test the hypothesis that healthy obesity still carried increased risk for hypertension and diabetes. Methods: Study subjects consisted of Japanese adults between 30 and 85 years old were enrolled at a hospital and available at enrollment (2004) and at 5-year follow-up (2009). Subjects were excluded if they were hypertensive, diabetic, had a medication for dyslipidemia and/or gout or hyperuricemia in 2004. We divided the study subjects into BMI ≥25 kg/m 2 and BMI <25 kg/m 2 , and compared the cumulative incidences of hypertension and diabetes over 5 years. Moreover, we performed a second analysis to determine if elevated serum uric acid provided additional risk for developing hypertension or diabetes, using uric acid of >7 mg/dL as hyperuricemia. Results: We analyzed 9,726 subjects (49±10 years, 4,160 men). Our primary finding was that healthy obesity carried increased risk for hypertension and diabetes compared to lean/normal subjects with similar risk factors, but the overall risk was lower compared to obese subjects and metabolic syndrome (Table) . An elevated uric acid was found to be an independent risk factor for the development of hypertension and diabetes in the lean/normal group (hypertension: 28.4% vs 14.6%, p<0.001; diabetes: 9.5% vs 2.6%, p<0.001), but not the obese group (hypertension: 19.8% vs 18.8%, p=0.65; diabetes: 6.6% vs 4.1%, p=0.078). There are significantly differences between groups (p<0.001).
Incidence of hypertension and diabetes

Conclusion:
Healthy obesity (obesity in the absence of metabolic syndrome) confers increased risk for hypertension and diabetes. An elevated uric acid in the absence of obesity also confers risk for hypertension and diabetes in lean/normal subjects but not in obese subjects. These data support the hypothesis that "healthy" obesity is not healthy, and that obesity remains a strong risk factor for hypertension and diabetes. In lean/normal subjects, the addition of uric acid levels can provide useful predictive value for risk for hypertension and diabetes. Purpose: To analyze birth weight (BW) and its association with high blood pressure (HBP) and body mass index (BMI) in students aged 10 to 15 years from public schools in Brazil. Methods: Cross-sectional study. BW was obtained through information provided by the parents or guardians. LBW was defined as BW ≤2,500 g. BP was measured three times by oscilometric method with OMROM HEM-1720 automatic monitor. HBP was defined when systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) on the third measurement was ≥p95 for age, gender and height percentile. HBP was further categorized into: isolated systolic hypertension (ISH), combined systolic/diastolic hypertension (SDH), and isolated diastolic hypertension (IDH 
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